C (P⬍.05) SA C / C (P⬍.05) SAF SA C / S (P⬍.001) SA / Group Screened-AssessedFollowed (nⴝ2032) Screened-Assessed (nⴝ1181) Screened-PositiveOnly (nⴝ149) Control Group / Study Group Cost Maternal / S SAF SA / S (P⬍.05) SAF SA / S (P⬍.001) SAF SA C / C (P⬍.05) SAF SA / Study Group Cost Infant / The Permanente Medical Group / C (P⬍.001) SA / Kaiser Permanente Northern California Institutional Review / C (P⬍.001) SAF SA / SA SAF SA / S (P⬍.05) SA / Screened-Positive-Only Control Group / Kaiser Permanente Northern California / Kaiser Permanente Northern California Community Benefits Program / C SAF SA / C (P⬍.05) SA / SAF SA / S SA / S (P⬍.001) SAF SA / /
Country
United States / /
Currency
USD / / /
Facility
Outpatient pharmacy No / Outpatient pharmacy Screened / Pharmacy Subtotal Total / The American College of Obstetricians / Outpatient pharmacy Subtotal Total Utilization Infants / Science University / Outpatient pharmacy / Pharmacy No / /
IndustryTerm
control groups / chemical / /
MedicalCondition
MS / /
Organization
The American College / American Academy / Centers for Disease Control and Prevention / /
Person
Yun-Yi Hung / Nancy C. Goler / Mary Anne Armstrong / Antepartum After / Veronica M. Osejo / Mental / Monica Haimowitz / Aaron B. Caughey / Birth Birth / /
Early Start A Cost–Beneficial Perinatal Substance Abuse Program Nancy C. Goler, MD, Mary Anne Armstrong, MA, Veronica M. Osejo, Monica Haimowitz, LCSW, and Aaron B. Caughey, MD, PhD OBJECTIVE: To conduct a cost– bene